These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22547351)

  • 1. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms.
    Finley SD; Popel AS
    AAPS J; 2012 Sep; 14(3):500-9. PubMed ID: 22547351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.
    Peach CJ; Mignone VW; Arruda MA; Alcobia DC; Hill SJ; Kilpatrick LE; Woolard J
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.
    Mac Gabhann F; Popel AS
    PLoS Comput Biol; 2006 Dec; 2(12):e180. PubMed ID: 17196035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-angiogenic isoforms of VEGF in health and disease.
    Qiu Y; Hoareau-Aveilla C; Oltean S; Harper SJ; Bates DO
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1207-13. PubMed ID: 19909248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
    Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y
    Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system.
    Ganta VC; Annex BH
    Expert Opin Ther Targets; 2021 May; 25(5):381-391. PubMed ID: 34098826
    [No Abstract]   [Full Text] [Related]  

  • 7. A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF
    Chu LH; Ganta VC; Choi MH; Chen G; Finley SD; Annex BH; Popel AS
    Sci Rep; 2016 Nov; 6():37030. PubMed ID: 27853189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.
    Finley SD; Engel-Stefanini MO; Imoukhuede PI; Popel AS
    BMC Syst Biol; 2011 Nov; 5():193. PubMed ID: 22104283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.
    Catena R; Larzabal L; Larrayoz M; Molina E; Hermida J; Agorreta J; Montes R; Pio R; Montuenga LM; Calvo A
    Mol Cancer; 2010 Dec; 9():320. PubMed ID: 21194429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model.
    Mac Gabhann F; Popel AS
    Am J Physiol Heart Circ Physiol; 2005 Jun; 288(6):H2851-60. PubMed ID: 15708957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-A splice variants bind VEGFRs with differential affinities.
    Mamer SB; Wittenkeller A; Imoukhuede PI
    Sci Rep; 2020 Sep; 10(1):14413. PubMed ID: 32879419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
    Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling.
    Stefanini MO; Wu FT; Mac Gabhann F; Popel AS
    PLoS Comput Biol; 2009 Dec; 5(12):e1000622. PubMed ID: 20041209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of manipulating VEGF splice isoforms in oncology.
    Rennel ES; Harper SJ; Bates DO
    Future Oncol; 2009 Jun; 5(5):703-12. PubMed ID: 19519209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropilin-1 in the mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during implantation.
    Halder JB; Zhao X; Soker S; Paria BC; Klagsbrun M; Das SK; Dey SK
    Genesis; 2000 Mar; 26(3):213-24. PubMed ID: 10705382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
    Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
    J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.
    Lin SW; Huang SC; Kuo HM; Chen CH; Ma YL; Chu TH; Bee YS; Wang EM; Wu CY; Sung PJ; Wen ZH; Wu DC; Sheu JH; Tai MH
    Mar Drugs; 2015 Feb; 13(2):861-78. PubMed ID: 25668036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the ligand-binding properties of fluorescent VEGF-A isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET.
    Peach CJ; Kilpatrick LE; Woolard J; Hill SJ
    Br J Pharmacol; 2019 Sep; 176(17):3220-3235. PubMed ID: 31162634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.